2Hopkins L, Smaill F. Antibiotic prophylaxis regimens and drugs for cesarean section ( Cochrane Review) [ EB/OL ]. http://update-software. com/abstracts/AB001136. htm, 2004 - 6 - 10.
3Christopher J.Dunne,Greg L.Plosker.Insulin Lispro a pharmacoeconomic review of its use in Diabetes Mellitus[J].Pharmacoeconomics,2002,20 (14):989-1025.
4Lubor Golan,John.D Birkmeyer,H.Glbert Welch.The cost -effectiveness of treating all patients with type2 diabetes with Angiotensin-converting enzyme inhibitors[J].Annals of internal medicine,1999,131 (9):660-667.
5Mark Lamotte,Myriam Nechelput,Lieven Annemans et al.A health economic model to assess the long-term effects and costeffectiveness of Orlistat in Obese type 2 Diabetic patients[J].Dia-betescare,2002,25 (2):303-308.
6TreeAge software,Inc.TreeAge Pro user's manual.TreeAge software,Inc.2004
7TreeAge software,Inc.TreeAge Pro healthcare module user's manual.TreeAge software,Inc.2004.
8D Walker,Ja Fox-Rushby.Allowing for uncertainty in economic evaluations:qualitative sensitivity analysis[J].Health policy and planning,2001,16 (4):435-443.
9Dave Smith,Hugn Grvelle.The practice of discounting economic evaluation of health care intervention[R].Center for health economic technical paper series 19,university of York; 2000.
